Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.

Dequeker, J; Hawkey, C; Kahan, A; Steinbrück, K; Alegre, C; Baumelou, E; Bégaud, B; Isomäki, H; Littlejohn, G; Mau, J; Papazoglou, S

Dequeker, J; Hawkey, C; Kahan, A; Steinbrück, K; Alegre, C; Baumelou, E; Bégaud, B; Isomäki, H; Littlejohn, G; Mau, J; Papazoglou, S.

Affiliation

Dequeker J; Division of Rheumatology, University Hospitals, K.U. Leuven, Belgium.

Br J Rheumatol ; 37(9): 946-51, 1998 Sep.

Article in En | MEDLINE | ID: mdl-9783758

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Osteoarthritis / Thiazines / Thiazoles / Piroxicam / Anti-Inflammatory Agents, Non-Steroidal / Cyclooxygenase Inhibitors / Gastrointestinal Diseases Type of study: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Rheumatol Year: 1998 Document type: Article Affiliation country:

Search on Google

Add to My VHL

XML

PubMed Links